
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Losartan Potassium
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kwality Pharma Gains on Securing RCGM Approval for Erythropoietin
Details : Kwality Pharmaceuticals gains RCGM approval for preclinical toxicity studies of recombinant Erythropoietin, advancing its biologics portfolio and targeting CKD-related anemia treatment.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 02, 2025
Lead Product(s) : Losartan Potassium
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tamoxifen Citrate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kwality Pharma Gains on Securing SAHPRA Approval for Tamoxifen Tablet
Details : Tamoxifen is a small molecule acts as an Estrogen receptor modulator, which is being investigated for the treatment of hormone receptor-positive breast cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 23, 2024
Lead Product(s) : Tamoxifen Citrate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kwality Pharma Gains Greece Approval for Leuprorelin Acetate Injectable Suspension
Details : Luprodex (leuprorelin acetate) is a gonadotropin releasing hormone (GnRH) agonist indicated for palliative treatment of advanced prostatic cancer.
Product Name : Luprodex
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
November 07, 2024
Lead Product(s) : Leuprolide Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
